Oric Pharmaceuticals Valuation
| ORIC Stock | USD 9.96 0.65 6.13% |
At this time, the company appears to be undervalued. Oric Pharmaceuticals holds a recent Real Value of $12.37 per share. The prevailing price of the company is $9.96. Our model determines the value of Oric Pharmaceuticals from analyzing the company fundamentals such as Return On Equity of -0.4, shares outstanding of 97.39 M, and Shares Owned By Institutions of 93.29 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Oric Pharmaceuticals' valuation include:
Undervalued
Today
Please note that Oric Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Oric Pharmaceuticals is based on 3 months time horizon. Increasing Oric Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Oric Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Oric Stock. However, Oric Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.96 | Real 12.37 | Target 21.0 | Hype 10.28 | Naive 7.95 |
The real value of Oric Stock, also known as its intrinsic value, is the underlying worth of Oric Pharmaceuticals Company, which is reflected in its stock price. It is based on Oric Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Oric Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Oric Pharmaceuticals helps investors to forecast how Oric stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Oric Pharmaceuticals more accurately as focusing exclusively on Oric Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Oric Pharmaceuticals' intrinsic value based on its ongoing forecasts of Oric Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Oric Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Oric Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Oric Pharmaceuticals Cash |
|
Oric Pharmaceuticals Total Value Analysis
Oric Pharmaceuticals is now forecasted to have valuation of 803.03 M with market capitalization of 1.03 B, debt of 3.18 M, and cash on hands of 227.06 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Oric Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
803.03 M | 1.03 B | 3.18 M | 227.06 M |
Oric Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Oric is to check how much profit was generated for every dollar of assets it reports. Oric Pharmaceuticals holds a negative application of assets of -0.25 pct., losing $0.002523 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Oric Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Oric Pharmaceuticals Profitability Analysis
Based on Oric Pharmaceuticals' profitability indicators, Oric Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Oric Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 2019-03-31 | Previous Quarter -36.4 M | Current Value -32.6 M | Quarterly Volatility 9.3 M |
For Oric Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oric Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oric Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oric Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oric Pharmaceuticals over time as well as its relative position and ranking within its peers.
Oric Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Oric Pharmaceuticals is estimated to be -0.374 with future projections ranging from a low of -0.54 to a high of -0.3. Oric Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at -1.65. Please be aware that the consensus of earnings estimates for Oric Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Oric Pharmaceuticals Earnings Estimation Breakdown
The calculation of Oric Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Oric Pharmaceuticals is estimated to be -0.374 with the future projection ranging from a low of -0.54 to a high of -0.3. Please be aware that this consensus of annual earnings estimates for Oric Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.54 Lowest | Expected EPS | -0.3 Highest |
Oric Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Oric Pharmaceuticals' value are higher than the current market price of the Oric Pharmaceuticals stock. In this case, investors may conclude that Oric Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Oric Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 15 | 74.13% | 0.0 | -0.374 | -1.65 |
Oric Pharmaceuticals Ownership Allocation
The majority of Oric Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Oric Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Oric Pharmaceuticals. Please pay attention to any change in the institutional holdings of Oric Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Oric Pharmaceuticals Profitability Analysis
Net Loss for the year was (127.85 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Oric Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Oric Pharmaceuticals and how it compares across the competition.
About Oric Pharmaceuticals Valuation
The stock valuation mechanism determines Oric Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Oric Pharmaceuticals. We calculate exposure to Oric Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Oric Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -996.3 K | -1 M |
Oric Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Oric Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Oric we look at many different elements of the entity such as Oric's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Oric Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Oric Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Oric Pharmaceuticals' worth.Complementary Tools for Oric Stock analysis
When running Oric Pharmaceuticals' price analysis, check to measure Oric Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oric Pharmaceuticals is operating at the current time. Most of Oric Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oric Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oric Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oric Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |